TR201700665A2 - The composition of a drug for use in the treatment of acute and chronic sinusitis - Google Patents
The composition of a drug for use in the treatment of acute and chronic sinusitis Download PDFInfo
- Publication number
- TR201700665A2 TR201700665A2 TR2017/00665A TR201700665A TR201700665A2 TR 201700665 A2 TR201700665 A2 TR 201700665A2 TR 2017/00665 A TR2017/00665 A TR 2017/00665A TR 201700665 A TR201700665 A TR 201700665A TR 201700665 A2 TR201700665 A2 TR 201700665A2
- Authority
- TR
- Turkey
- Prior art keywords
- drug composition
- treatment
- composition
- drug
- sinusitis
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 40
- 239000003814 drug Substances 0.000 title claims description 33
- 229940079593 drug Drugs 0.000 title claims description 31
- 206010001076 Acute sinusitis Diseases 0.000 title description 5
- 206010009137 Chronic sinusitis Diseases 0.000 title description 5
- 208000027157 chronic rhinosinusitis Diseases 0.000 title description 5
- 230000001154 acute effect Effects 0.000 title description 4
- 201000009890 sinusitis Diseases 0.000 claims abstract description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 9
- -1 salt group compound Chemical class 0.000 claims abstract description 8
- 208000015181 infectious disease Diseases 0.000 claims abstract description 4
- 210000003097 mucus Anatomy 0.000 claims abstract description 4
- 150000002500 ions Chemical class 0.000 claims description 7
- 239000011651 chromium Substances 0.000 claims description 6
- 150000003839 salts Chemical group 0.000 claims description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 3
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 3
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 229910052782 aluminium Inorganic materials 0.000 claims description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 3
- 229910052792 caesium Inorganic materials 0.000 claims description 3
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 claims description 3
- 229910052804 chromium Inorganic materials 0.000 claims description 3
- 229910052733 gallium Inorganic materials 0.000 claims description 3
- 229910052738 indium Inorganic materials 0.000 claims description 3
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 claims description 3
- 150000001455 metallic ions Chemical class 0.000 claims description 3
- 229910052701 rubidium Inorganic materials 0.000 claims description 3
- IGLNJRXAVVLDKE-UHFFFAOYSA-N rubidium atom Chemical compound [Rb] IGLNJRXAVVLDKE-UHFFFAOYSA-N 0.000 claims description 3
- 229910052720 vanadium Inorganic materials 0.000 claims description 3
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 claims description 3
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 claims description 2
- BUACSMWVFUNQET-UHFFFAOYSA-H dialuminum;trisulfate;hydrate Chemical compound O.[Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O BUACSMWVFUNQET-UHFFFAOYSA-H 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 abstract description 7
- 229940088710 antibiotic agent Drugs 0.000 abstract description 7
- 230000000694 effects Effects 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000001331 nose Anatomy 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010038687 Respiratory distress Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 210000001180 ethmoid sinus Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001214 frontal sinus Anatomy 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000002070 germicidal effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000004086 maxillary sinus Anatomy 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 210000003718 sphenoid sinus Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Bu buluş, özellikle sinüzit tedavisinde sinüsler içerisinde bulunan enfekte olmuş mukusun drene edilmesi ve o bölgedeki enfeksiyonun kurumasını sağlamak üzere antibiyotiklere alternatif oluşturmak ve tedavi sürecinde kişiye farklı bir zarar vermemek için sinüzit tedavisinde kullanılmak üzere su ve en az bir çift tuz grubu bileşik içeren ve [Me+1Me+3(SO4)2.12H2O] formülasyonuna sahip bir ilaç bileşimi ile ilgilidir.The present invention provides water and at least one double salt group compound for use in the treatment of sinusitis in order to provide an alternative to antibiotics to drain the infected mucus contained in the sinuses and to allow the infection to dry out at that site, and not to cause any further harm to the individual during treatment. + 1Me + 3 (SO4) 2.12H2O].
Description
TARIFNAME AKUT VE KRONIK SINUZIT TEDAVISINDE KULLANILMAK UZERE BIR iLAç BILESIMI Bulusun Ilgili Oldugu Teknik Alan: Bulus, akut ve kronik sinüzit tedavisinde antibiyotik yerine ve/veya antibiyotiklere yardimci olacak sekilde kullanilmak üzere bir ilaç bilesimi ile ilgilidir. DESCRIPTION A MEDICINE COMPOSITION TO BE USED IN THE TREATMENT OF ACUTE AND CHRONIC SINUSITIS Technical Field of Invention: The invention is a substitute for and/or adjunct antibiotics in the treatment of acute and chronic sinusitis. relates to a medicament composition for use as intended.
Teknigin Bilinen Durumu: Sinüsler, kafa kemiklerinin içine yerlesen ve agizlari (yani kanallari) burun içine açilan, içi hava dolu kemik bosluklaridir. Dogumdan sonra bir kismi (ethmoid ve maksiler sinüsler) olusur, digerleri sonradan olusur ( sfenoid ve frontal sinüsler ) ve ergenlikte tamamlanirlar. Sesin tinisini, karakterini saglamasinin yani sira burundan geçen havanin nemlenmesine ve vücut isisina yaklasmasina, içi hava dolu oldugu için kafanin agirligini azaltip basin dik durmasina yardimci olurlar. State of the Art: Sinuses, internal air that settles in the skull bones and opens their mouths (i.e. channels) into the nose. filled bone cavities. After birth, some of them (ethmoid and maxillary sinuses) are formed, others are formed later (the sphenoid and frontal sinuses) and are completed at puberty. your voice In addition to providing its tone and character, it also helps to humidify the air passing through the nose and get closer to the heat, reduce the weight of the head because it is full of air and keep the head upright they are helpful.
Sinüs bosluklarini kaplayan mukozanin viral, bakteriyel ve mantar gibi etkenlerle iltihaplanmasina sinüzit denilmektedir. Sinüzitler; 2 haftadan kisa sürerse akut sinüzit, 2 ile 12 hafta arasi sürerse subakut sinüzit, 12 haftadan uzun sürerse kronik sinüzit olarak adlandirilmaktadir. The mucosa that covers the sinus cavities is affected by factors such as viral, bacterial and fungal. Inflammation is called sinusitis. Sinusitis; Acute sinusitis if it lasts less than 2 weeks, 2 to 12 subacute sinusitis if it lasts between 12 weeks, chronic sinusitis if it lasts longer than 12 weeks is named.
Günümüzde akut ve kronik sinüzit tedavisi zorlu bir süreç olarak bilinmektedir. Söz konusu rahatsizligin tedavisinde çogu zaman antibiyotikler kullanilmaktadir. Antibiyotiklerin vücut üzerinde bilinen birçok hafif ve agir yan etkileri bulunmaktadir. Today, the treatment of acute and chronic sinusitis is known as a difficult process. Aforementioned Antibiotics are often used to treat the disease. body of antibiotics It has many known mild and severe side effects.
Söz konusu tedavi sürecinde tedavi amaciyla 3. ve 4. kusak antibiyotikler kullanilmakta olup yan etkileri oldukça fazladir. Antibiyotik kullanimi esnasinda, bazi kisilerde hafiften siddetliye kadar degisen, hatta bazen 'Ölümcül olabilen yan etkiler ortaya çikabilir. Bunlar: sindirim sisteminde bulanti, kusma, ishal, hazimsizlik; sinir sisteminde duyu kusurlari; solunum sisteminde solunum sikintisi; dolasim sisteminde düsük tansiyon ve böbrekler ve karacigerde degisen derecelerde karaciger ve böbrek yetmezligi gibi negatif ve istenmeyen rahatsizliklardir. In the treatment process in question, 3rd and 4th generation antibiotics are used for treatment. side effects are very high. During the use of antibiotics, in some people mild to severe Side effects that vary as much as, sometimes even fatal, may occur. These are: digestion nausea, vomiting, diarrhea, indigestion; sensory defects in the nervous system; respiratory respiratory distress in the system; low blood pressure in the circulatory system and kidneys and liver negative and undesirable, such as varying degrees of liver and kidney failure. are inconveniences.
Teknigin bilinen durumunda sinüzit tedavisinde kullanilan söz konusu antibiyotiklerin belirtilen yan etkileri nedeniyle tedavi amaçli kullanimlari bir baska organi veya isleyisi tehlikeye sokmakta ve bir rahatsizlik için tedavi edici olarak kullanilirken diger bir rahatsizliga davetiye çikarmaktadirlar. In the state of the art, the mentioned antibiotics used in the treatment of sinusitis Because of their side effects, their therapeutic use may endanger another organ or functioning. sting and used as a therapeutic for one ailment, while inviting another ailment they are removing.
Teknigin bilinen durumunda yer alan söz konusu dezavantaj ve yetersizlikler sinüzit tedavisinde kullanilmak üzere antibiyotik etki içermeyen bir ilaç bilesimi gelistirilmesini zorunlu kilmaktadir. tedavisinde kullanilmak üzere bir spreyin dagitim ve üretim yöntemi anlatilmaktadir. Söz konusu dokümanda bulus konusu ile benzer veya bulusun yeniligini öldürecek herhangi bir benzerlik bulunmamaktadir. The mentioned disadvantages and inadequacies in the state of the art are sinusitis. It is obligatory to develop a drug composition that does not contain an antibiotic effect for use in the treatment of it builds. The method of distribution and production of a spray for use in the treatment of Promise The subject of the document is similar to the subject of the invention or any other thing that will kill the novelty of the invention. there is no similarity.
Teknigin bilinen durumunda yer alan bir diger CN101288706 yayin numarali dokümanda, nazal sinüzit tedavisinde kullanilmak üzere bir ilaç bilesimi anlatilmaktadir. Ancak yapi ve avantaj itibariyle söz konusu dokümanda yer alan ilaç bilesimi ile bulus konusu bilesim ile gelistirilen ilaç yapisi herhangi bir sekilde benzerlik göstermemektedir. In another document with the publication number CN101288706 in the state of the art, A drug composition is described for use in the treatment of nasal sinusitis. However, do and advantageously, with the drug composition in the document in question and the composition that is the subject of the invention. The developed drug structure does not show any similarity in any way.
Bulusun Kisa Açiklamasi: Bulusun amaci, özellikle sinüzit tedavisinde sinüsler içerisinde bulunan enfekte olmus mukusun drene edilmesi ve 0 bölgedeki enfeksiyonun kurumasini saglamak üzere bir ilaç bilesimi gerçeklestirmektir. Brief Description of the Invention: The aim of the invention is to treat infected patients in the sinuses, especially in the treatment of sinusitis. a medicine to drain mucus and dry the infection in the 0 area to realize the composition.
Bulus konusu ilaç bilesimi, grip ve soguk alginliginin semptomatik tedavisinde (burun kanallarinin açilmasinda) de kullanilabilmektedir. The drug composition of the invention is used in the symptomatic treatment of flu and colds (nasal can also be used for opening channels).
Bulus konusu ilaç bilesimi, tedavi edici olmasi için minumum 3 gün ve 3 doz seklinde alinmasi maximum 4 gün 4 doz alinmasi yeterlidir. Söz konusu bilesim içilebilir olmasi nedeniyle toksik riski içermemektedir. The drug compound of the invention must be taken in 3 doses for a minimum of 3 days in order to be therapeutic. It is sufficient to take 4 doses for a maximum of 4 days. The composition in question is toxic as it is potable. does not involve risk.
Bulus konusu ilaç bilesimini 8 ila 70 yas araligindaki her insan rahatlikla tüketebilmektedir. Every person between the ages of 8 and 70 can easily consume the drug composition of the invention.
Bulus konusu ilaç bilesimi, vazokonstriksiyon yapmaktadir. Söz konusu bilesim, mikrop öldürücü özellige sahiptir. Dogal olmasi nedeniyle kimyasal maddelerin yapmis oldugu yan etkilerden uzaktir. The drug composition of the invention causes vasoconstriction. The composition in question is microbe It has lethal properties. Since it is natural, the side effects of chemical substances away from the effects.
Bulus konusu ilaç bilesimi, burun içerisine kolayca uygulanabilmektedir. Dogal ve islenmemis halde kullanilir ve tedavi maliyetini düsürür. The drug composition of the invention can be easily administered intranasally. Natural and unprocessed It is used in good condition and reduces the cost of treatment.
Bulus konusu ilaç bilesimi, ayni zamanda mikrop öldürücü, diyare gidericidir. Kani durdurma etkisi vardir ve antiseptik 'özellige sahiptir. The drug composition of the invention is also germicidal and antidiarrheal. stop the blood It has an effect and has antiseptic properties.
Söz konusu bilesimin etkisini daha iyi gösterebilmesi için uygulama öncesi burun ile ilgili olarak nazal steroit kullanilmamasi önerilmektedir. Eger nazal steroit kullanildi ise minimum 4 saat sonra bulus konusu bilesim tatbik edilmelidir. In order to show the effect of the said composition better, it should be done about the nose before the application. It is recommended not to use nasal steroids. If nasal steroids were used, a minimum of 4 hours then the subject matter composition must be applied.
Bulus konusu ilaç bilesimi sadece ürün kanalindan tatbik edilmelidir. Oda sicakliginda saklanmali ve çocuklarin ulasamayacagi yerlerde saklanmalidir. Ayrica söz konusu bilesimi, 8 yas alti çocuklarin kullanmamasi bnerilmektedir. The drug composition of the invention should only be administered through the product channel. At room temperature should be kept out of the reach of children. In addition, the said composition, 8 It is recommended not to be used by children under age.
Bulus konusu ilaç bilesimi, özellikle sinüzit tedavisinde sinüsler içerisinde bulunan enfekte olmus mukusun drene edilmesi ve o bölgedeki enfeksiyonun kurumasini saglamak üzere su ve etken madde olarak en az bir çift tuz grubu bilesik içermektedir ve [Me+1Me+3(SO4)2.12H20] formülasyonuna sahiptir. The drug composition of the invention, especially in the treatment of sinusitis, infected infected cells in the sinuses. water to drain the dead mucus and dry the infection in that area. and contains at least one double salt group compound as active ingredient [Me+1Me+3(SO4)2.12H20] has formulation.
Bulus konusu ilaç bilesimi, içeriginde bulunan tuz grubundan +1 ve +3 degerlikli en az iki adet metalik iyon içermektedir. The drug compound which is the subject of the invention is composed of at least two salts of +1 and +3 value from the salt group it contains. contains metallic ions.
Bulus konusu ilaç bilesiminin içerdigi +1 degerlikli bilesen (Me”); Potasyum (K*) veya Amonyum (NH4*) veya Rubidyum (Rb*) veya Sezyum (Cs*) iyonlarindan en az bir tanesi olabilmektedir. +1 value component (Me”) contained in the drug composition of the invention; Potassium (K*) or At least one of the Ammonium (NH4*) or Rubidium (Rb*) or Cesium (Cs*) ions can happen.
Bulus konusu ilaç bilesiminin içerdigi, +3 degerlikli bilesen (Me*3); Alüminyum (AI*3) veya Ferrik (Fe*3) veya Galyum (Ga*3) veya Indiyum (In*3) veya Krom (Cr*3) veya Vanadyum (V*'°`) iyonlarindan en az bir tanesi olabilmektedir. The +3 valence component (Me*3) contained in the drug composition which is the subject of the invention; Aluminum (AI*3) or Ferric (Fe*3) or Gallium (Ga*3) or Indium (In*3) or Chromium (Cr*3) or Vanadium (V*'°`) at least one of its ions.
Bulus konusu ilaç bilesimi, içeriginde agirlikça %60 ila %95 oraninda su içermektedir. The drug composition which is the subject of the invention contains water at the rate of 60% to 95% by weight.
Bulus konusu ilaç bilesimi, içeriginde agirlikça %5 ila 40 oraninda çift tuz grubu bilesiklerden Bulusun Ayrintili Açiklamasi: Bulus konusu ilaç bilesimi, su ve etken madde olarak en az bir çift tuz grubu bilesik içermektedir. The drug composition which is the subject of the invention is composed of double salt group compounds at a rate of 5 to 40% by weight. Detailed Description of the Invention: The drug composition of the invention is water and at least one double salt group compound as active ingredient. contains.
Bulus konusu ilaç bilesimi, deiyonize su içermektedir. The drug composition of the invention contains deionized water.
Bulus konusu bilesimin bulusun temel uygulamasinda genel formülü [Me”Me*3(SO4)2.12H20] seklindedir. The general formula of the subject compound in the basic application of the invention is [Me”Me*3(SO4)2.12H20] is in the form.
Bulus konusu bilesim, içeriginde bulunan tuz grubunda en az iki adet metalik iyon içermektedir. The composition subject to the invention contains at least two metallic ions in the salt group it contains.
Söz konusu metal iyonlar, +1 ve +3 degerlikli metallerin iyonlaridir. The metal ions in question are ions of +1 and +3 valence metals.
Bulus konusu ilaç bilesiminin içerdigi +1 degerlikli bilesen (Me*1); Potasyum (K+) veya Amonyum (NH4*) veya Rubidyum (Rb*) veya Sezyum (Cs*) iyonlarindan en az bir tanesi olabilmektedir. +1 value component (Me*1) contained in the drug composition of the invention; Potassium (K+) or At least one of the Ammonium (NH4*) or Rubidium (Rb*) or Cesium (Cs*) ions can happen.
Bulus konusu ilaç bilesiminin içerdigi +3 degerlikli bilesen (Me+3); Alüminyum (AI*3) veya Ferrik (Fe*3) veya Galyum (Ga*3) veya Indiyum (In*3) veya Krom (Cr*3) veya Vanadyum (V*3) iyonlarindan en az bir tanesi olabilmektedir. The +3-valued component (Me+3) contained in the drug composition which is the subject of the invention; Aluminum (AI*3) or Ferric (Fe*3) or Gallium (Ga*3) or Indium (In*3) or Chromium (Cr*3) or Vanadium (V*3) at least one of its ions.
Bulus konusu ilaç bilesimi, agirlikça %60 ila %95 oraninda su içermektedir. The drug composition of the invention contains between 60% and 95% water by weight.
Bulus konusu ilaç bilesimi, agirlikça %5 ila 40 oraninda çift tuz grubu içermektedir. The drug composition of the invention contains 5 to 40% by weight of double salt groups.
Bulus konusu ilaç bilesimini olusturmak için bulusun bir uygulamasinda, oda sicakliginda 500- 1000 -ml deiyonize suya, 5 ila 40 gr çift tuz bilesigi eklenerek 72 saat süreyle karisim homojenize hale getirilmektedir. Söz konusu çift tuz bilesigi bulusun tercih edilen bir uygulamasinda sap olarak adlandirilan Alüminyum Sülfat'tir. In one embodiment of the invention to form the inventive drug composition, 500- Add 5 to 40 g of double salt compound to 1000 ml deionized water and mix for 72 hours. is homogenized. Said double salt compound is a preferred form of the invention. It is Aluminum Sulphate, which is called sap in its application.
Bulus, yukarida açiklanan uygulamalar ile sinirli olmayip teknikte uzman kisi bulusun farkli uygulamalarini ortaya koyabilecektir. Dolayisiyla bulusta korunmak istenen detaylar istemler kapsaminda degerlendirilmelidir. The invention is not limited to the above-described embodiments, but one skilled in the art may consider the invention to be different. demonstrate its applications. Therefore, the details to be protected in the invention are the claims. should be evaluated within the scope of
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TR2017/00665A TR201700665A2 (en) | 2017-01-17 | 2017-01-17 | The composition of a drug for use in the treatment of acute and chronic sinusitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TR2017/00665A TR201700665A2 (en) | 2017-01-17 | 2017-01-17 | The composition of a drug for use in the treatment of acute and chronic sinusitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR201700665A2 true TR201700665A2 (en) | 2018-07-23 |
Family
ID=64606131
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2017/00665A TR201700665A2 (en) | 2017-01-17 | 2017-01-17 | The composition of a drug for use in the treatment of acute and chronic sinusitis |
Country Status (1)
| Country | Link |
|---|---|
| TR (1) | TR201700665A2 (en) |
-
2017
- 2017-01-17 TR TR2017/00665A patent/TR201700665A2/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201992759A1 (en) | ASSOCIATION INCLUDING OXYGEN AND HYALURONIC ACID, FOR LOCAL VAGINAL USE | |
| EA039000B1 (en) | Composition having antiviral effect | |
| TR201700665A2 (en) | The composition of a drug for use in the treatment of acute and chronic sinusitis | |
| Ashok et al. | Bactericidal effect of different anti-microbial agents on fusobacterium nucleatum biofilm | |
| RU2665959C1 (en) | Spray for emergency prevention of acute respiratory viral infections | |
| AR045070A1 (en) | PREPARED PHARMACEUTICAL TOPICS OF ASCORBIC ACID WITH POST-ANTIMICOTIC EFFECT | |
| RU2790837C2 (en) | Spray for treatment of infected and uninfected wounds in type i diabetes mellitus | |
| Choi et al. | Assessment of clinical outcome in dogs with naturally infected with dirofilaria immitis after american heartworm society protocol vs slow kill method | |
| EA028540B1 (en) | Application of adsorbed drone brood homogenate and of vitamin dor d-group vitamins and/or active metabolites thereof for preventing and treating viral diseases | |
| Avdeev et al. | Efficacy and Safety of Nebulized Surfactant-BL as a Part of Complex Therapy of COVID-19-associated ARDS: A Multicenter, Open-label Randomized Controlled Trial | |
| RU2646797C2 (en) | Method for treatment of postoperative wound complications under conditions of systemic inflammatory reaction after caesarean section | |
| RU2021121514A (en) | METHOD FOR TREATMENT OF CORONAVIRUS INFECTION COVID-19 IN HUMANS WITH MEDICATIONS WITH A NEW PURPOSE | |
| US20170326123A1 (en) | Throat solution for treatment of cold, flu and sore throat | |
| Gu et al. | Ozone Sterilizer for Treatment and Health Care | |
| BR112021026839A2 (en) | Pharmaceutical compositions for treating and preventing an influenza virus infectious disease | |
| CN104324214B (en) | Halitosis navel paster and preparation method thereof | |
| ES2238937B2 (en) | Liquid natural general purpose infection inhibitor comprises mineral water, alcohol and vegetable matter in a specific mix | |
| TWI410250B (en) | Glutathione as antidote of tetramethylammonium hydroxide | |
| TURNBULL et al. | SINUSITIS AND INFECTIONS SECONDARY TO THE COMMON COLD: TREATMENT WITH STABILIZED AQUEOUS SOLUTION OF SULFATHIAZOLE SODIUM WITH DESOXYEPHEDRINE HYDROCHLORIDE | |
| RU2270692C1 (en) | Prolonged interferon solution | |
| CN104906577B (en) | A kind of pharmaceutical composition for eradicating helicobacter pylori and preparation method thereof | |
| US20210308080A1 (en) | Transient induced systemic acidosis (tisa) to treat virus infections | |
| TR201810733A2 (en) | OIL BASED, BUMPER EFFECT SPEED BLEEDING SPRAY FOR NOSE AND OPEN WOUND HEMORRHAGE | |
| TR201811928A2 (en) | COLD HEALTH AND GRIBAL INFECTION TREATMENT SYRUP | |
| RU2540436C1 (en) | Method of prevention of respiratory diseases of calves using integrated application of antiviral preparation iodantipyrine and mineral feed supplement vitartil |